Form 4: Immunome Inc. Chief Technology Officer Philip Tsai Reports Transaction
SEC Form 4 Filing
Philip Tsai, Chief Technology Officer of Immunome Inc., reports the acquisition and disposal of common stock on March 24, 2025.
Summary
- On March 24, 2025, Philip Tsai, the Chief Technology Officer of Immunome Inc., engaged in a transaction involving the company's common stock.
- Tsai acquired 12,300 shares of common stock at a price of $8.42 per share.
- Following the reported transaction, Tsai's beneficial ownership of Immunome Inc. common stock is 33,300 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a transaction by a company insider. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, ensuring transparency and compliance with securities regulations.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 03/24/2025 | Date of transaction: Philip Tsai acquired and disposed of Immunome Inc. common stock. |
| 03/25/2025 | Date of signature: Form 4 signed by Sandra Stoneman, Attorney-in-Fact. |
Keywords
Immunome Inc., IMNM, Philip Tsai, Chief Technology Officer, Form 4, Beneficial Ownership, Stock Transaction, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.